Skip to main content

Vyant Bio, Inc. (VYNT)

NASDAQ: VYNT · IEX Real-Time Price · USD
1.68
-0.15 (-8.20%)
At close: Dec 3, 2021 4:00 PM
1.69
0.01 (0.60%)
After-hours:Dec 3, 2021 5:58 PM EST

Company Description

Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development.

StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening.

The company, through its subsidiary, vivoPharm, offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages by the pharmaceutical industry, biotechnology companies, and academic research centers.

vivoPharm specializes in conducting studies to guide drug development, starting from compound libraries and ending with a set of in vitro and in vivo data and reports, as needed for investigational new drug filings.

The company is based in Cherry Hill, New Jersey.

Vyant Bio, Inc.
Vyant Bio Logo
CountryUnited States
Founded1999
IPO DateApr 5, 2013
IndustryBiotechnology
SectorHealthcare
Employees40
CEOJohn Roberts

Contact Details

Address:
201 State Rt 17 Fl 2
Rutherford, New Jersey 07070-2597
United States
Phone201 479 1357
Websitevyantbio.com

Stock Details

Ticker SymbolVYNT
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001349929

Key Executives

NamePosition
Yung-Ping Yeh M.B.A., M.S., P.M.P.Co-Founder, Chief Innovation Officer and Director
Andrew D.C. LaFrence CPA, CPAChief Financial Officer and Chief Operating Officer
Dr. Robert J. PetcavichChief Science Advisor and Director
John A. Roberts M.B.A., MBAPresident, Chief Executive Officer and Director
Dr. Robert Thomas Fremeau Jr., Ph.D.Chief Scientific Officer
Dr. Ralf Brandt Ph.D.President of Discovery and Early Development Services
Dr. Barb Jones Ph.D.Senior Vice President of Scientific Operations and Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Nov 24, 20214Statement of changes in beneficial ownership of securities
Nov 24, 20214Statement of changes in beneficial ownership of securities
Nov 23, 20214Statement of changes in beneficial ownership of securities
Nov 17, 20214Statement of changes in beneficial ownership of securities
Nov 17, 20213Initial statement of beneficial ownership of securities
Nov 12, 202110-QQuarterly report [Sections 13 or 15(d)]
Oct 28, 20214Statement of changes in beneficial ownership of securities
Oct 26, 20218-KCurrent report
Sep 30, 20214Statement of changes in beneficial ownership of securities
Aug 27, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings